REFERENCES
- World Health Organisation. Community control of hereditary anemias: memorandum from a WHO meeting. Bull World Health Organ 1983; 61(1)63–80
- Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16)2161–2183, [PUBMED], [INFOTRIEVE]
- Hoffbrand A.V. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol 2005; 18(2)299–317, [CROSSREF]
- Borgna-Pignatti C, Rugolotto S., De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850(30)227–231, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L. Effective chelation of iron in β-thalassaemia with the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Br Med J 1987; 295(6612)1509–1512
- Kontoghiorghes GJ, Aldouri MA, Sheppard LN, Hoffbrand AV. 1, 2-Dimethyl-3-hydroxypyrid-4-one, on orally active chelator for the treatment of transfusional iron overload. Lancet 1987; 1(8545)1294–1295, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70(6)392–397, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses heart failure in patients with β-thalassemia major. Ann Hematol 2004; 83(7)471–473, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1998; 339(7)417–423, [PUBMED], [INFOTRIEVE], [CROSSREF]